Research and Markets: CNS Lymphoma - Pipeline Review, H1 2012
Research and Markets has announced the addition of Global Markets Direct's new report "CNS Lymphoma - Pipeline
Research and Markets: Indolent Lymphoma - Pipeline Review, H1 2012
Research and Markets has announced the addition of Global Markets Direct's new report "Indolent Lymphoma - Pip
Research and Markets: Burkitt Lymphoma - Pipeline Review, H1 2012
Research and Markets has announced the addition of Global Markets Direct's new report "Burkitt Lymphoma - Pipel
BiovaxID® Personalized Lymphoma Vaccine is Featured in Article Published in Scrip Intelligence
Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that an article was published in Scrip Intelligence reporting on Biovest’s regulatory plans for BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma.
Non-Hodgkin Lymphoma Risk Factors During Early Life
Older maternal age, low birth order, male gender, family characteristics, and high fetal growth are all factors that increase the risk of developing early life non-Hodgkin lymphoma (NHL), say researchers. According to the study, published in the Journal of National Cancer Institute, the incidence of NHL has increased significantly over the last 5 decades. Although the overall incidence began to ...